Welcome.
Are you a healthcare professional?

This website contains promotional information for Chiesi's respiratory products, and is intended solely for UK healthcare professionals. Please confirm below, or go back to the home page.

I am a UK healthcare professional No, take me back
UK-RES-2101606 August 2021

You are now leaving Chiesi's website

By clicking this link, you will be taken to a website that is not owned or controlled by Chiesi. Chiesi is not responsible for the content provided on that site.

Continue
Go back

UK-RES-2101574 August 2021

INTENDED FOR UK HEALTHCARE PROFESSIONALS ONLY
We don’t have a single solution to sustainability. We have many. Find out more
earth
We don’t have a single solution to sustainability. We have many. Find out more
Sustainability in respiratory care
Importance of device choice
Our actions
Advancing sustainability

Protecting patients and the planet

From being one of the first pharmaceutical companies with a chlorofluorocarbon (CFC)-free beclometasone dipropionate (BDP) treatment, to our ambitious investments in future respiratory innovations,1,2 we know action is needed to protect our planet – but not at the expense of the very best care for people with respiratory diseases.
Click here for Clenil® (beclometasone) Prescribing Information
At Chiesi, we believe true ‘sustainability’ can only be achieved with a broad array of projects that protect both patients and the planet. This holistic approach is key – and means we sometimes see things a little differently than other pharmaceutical companies.
We strive to consider every aspect of the long-term future of respiratory care for patients, healthcare professionals (HCPs) and the planet, for example:  
  • Providing a portfolio of pMDI and DPI devices – giving HCPs both prescribing options depending on patient needs
  • Encouraging inhaler prescribing that best suits the needs of the patient, and helping HCPs to involve patients in their treatment decisions
  • Offering educational and training support for HCPs within the NHS to support the implementation of national and local clinical guidelines
  • Investing millions in respiratory treatments with low global warming potential1
  • Supporting inhaler recycling projects across the UK,3 empowering patients to change the way they dispose of inhalers and return them to local pharmacies 
  • Pledging to become carbon neutral by 2035 by offsetting all greenhouse gas emissions generated by Chiesi – well ahead of the UK national target of 20504

Our approach to sustainability may surprise you.

To find out more about our initiatives, visit chiesi.uk.com
BDP: Beclometasone dipropionate; CFC: Chlorofluorocarbon; DPI: Dry powder inhaler; HFA: Hydrofluoroalkane; pMDI: Pressurised metered dose inhalers.

References:

  1. The way we act. Chiesi Sustainability Report 2019. Available at: https://www.chiesi.uk.com/pdf/Chiesi_Sustainability_Report_2019_ENG.pdf.
  2. PR Web. Chiesi Group Launch New Product Into UK £80 Million Asthma Market. July 26 2006. Available at: https://www.prweb.com/releases/2006/07/prweb415789.htm.
  3. NHS Long Term Plan. January 2019. Available at: https://www.longtermplan.nhs.uk/wp-content/uploads/2019/08/nhs-long-term-plan-version-1.2.pdf.
  4. Legislation.gov.uk. The Climate Change Act 2008 (2050 Target Amendment) Order 2019. Available at: https://www.legislation.gov.uk/ukdsi/2019/9780111187654.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Limited on 0800 0092329 (UK) or PV.UK@Chiesi.com.